Christopher Pettigrew is a seasoned professional with over 10 years of experience in biopharma corporate/business development and strategy. Currently serving as Senior Director of Business Development at GSK in Philadelphia, he has played a pivotal role in numerous high-profile transactions and strategic initiatives. His tenure at GSK includes successful acquisitions such as Bellus Health ($2bn) and Sierra Oncology ($1.9bn), as well as significant in-licensing deals and divestments. Pettigrew’s expertise extends to corporate strategy, having worked on projects like the spin-out of Haleon and the development of GSK’s new R&D strategy. 

Prior to his current role, he held positions as Corporate Strategy Director and R&D Operations, Planning, and Strategy Manager at GSK in London. His career also includes experience as a Senior Associate at Novasecta Ltd, a boutique biopharma strategy consulting firm, and as co-founder of Cytospan Technologies Corporation in Toronto. Pettigrew’s background in scientific research, gained during his time at the University of Toronto, complements his business acumen, making him a well-rounded leader in the pharmaceutical industry.